Results 141 to 150 of about 4,251 (181)

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia. [PDF]

Curr Hematol Malig Rep
Benrashid S, Woyach JA.
europepmc   +1 more source

Acquired angioedema due to C1 inhibitor deficiency: real-world clinical characteristics and treatment outcomes. [PDF]

Front Immunol
Toprak İD, Erdem S, Korkmaz P, Unal D, Yegit OO, Hormet Igde M, Çelik Kamacı Ş, Çetin O, Öztop N, Demir S, Tüzer C, Mastanzade M, Elverdi T, Sezgin ME, Kalayoğlu Beşışık S, Gelincik A.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Acalabrutinib

Reactions Weekly
  +17 more sources

Acalabrutinib

Reactions Weekly, 2023
  +7 more sources

Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization

ImmunoHorizons
The efficacy and safety of acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was evaluated in 2 phase 2 studies in hospitalized patients with coronavirus disease 2019 (COVID-19) who received acalabrutinib + best supportive care (BSC) versus BSC ...
Philip A Robinson, David J Park, Priti Patel   +2 more
exaly   +2 more sources